Mark Kozloff to Adenocarcinoma
This is a "connection" page, showing publications Mark Kozloff has written about Adenocarcinoma.
Connection Strength
0.308
-
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol. 2010 Mar; 5(3):354-60.
Score: 0.210
-
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.
Score: 0.059
-
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.
Score: 0.010
-
Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy. Cancer. 1983 Feb 01; 51(3):381-4.
Score: 0.008
-
Multimodality therapy of stage III adenocarcinoma of the breast. J Surg Oncol. 1983 Jan; 22(1):5-8.
Score: 0.008
-
Prognostic value of the estrogen receptor level in pathologic stage I and II adenocarcinoma of the breast. J Surg Oncol. 1982 Feb; 19(2):119-21.
Score: 0.007
-
Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin, and mitomycin C (FAM). Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):2049-51.
Score: 0.006